Danish pharmaceutical leader Novo Nordisk has transformed a legal confrontation with the telemedicine provider Hims & Hers into a collaborative venture. The agreement will see the platform discontinue marketing unauthorized versions of Novo Nordisk’s weight-loss medications and instead distribute the company’s original, approved products. This strategic shift not only opens a significant new distribution channel in the lucrative obesity treatment market but also serves to push back against unregulated competition.
Regulatory Landscape and Competitive Dynamics
This partnership emerges during a period of intensified regulatory scrutiny. The U.S. Food and Drug Administration (FDA) recently issued warning letters to several telemedicine companies concerning misleading advertising practices. Regulators have emphasized that individually compounded medications cannot be marketed as legitimate generic alternatives or clinically proven substitutes for approved brand-name drugs.
The move also strengthens Novo Nordisk’s position in its direct rivalry with Eli Lilly within the obesity treatment sector. To secure market share and attract self-paying patients, the company has strategically reduced prices for its treatments. Its Wegovy tablet has already recorded over 600,000 prescriptions since launch. The new collaboration with Hims & Hers is expected to further accelerate this demand by offering original products at standard self-pay rates.
From Litigation to Collaboration
Previously, in February, Novo Nordisk had filed a patent infringement lawsuit against Hims & Hers for marketing unauthorized versions of its GLP-1 receptor agonist drugs. That legal action has now been dismissed, though the pharmaceutical giant retains the right to reassert its claims in the future if necessary.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Under the new arrangement, Hims & Hers will focus on offering government-approved therapies, adding Novo Nordisk’s diabetes drug Ozempic and Wegovy injections and tablets to its portfolio. The platform will cease targeted promotion of GLP-1 alternatives but will maintain access in exceptional cases where physicians deem it clinically necessary for specific patients.
Share Buyback Program Progresses in Tandem
Alongside this strategic distribution realignment, Novo Nordisk continues to execute its substantial capital return initiative. The share repurchase program, which commenced in early February 2026, has a total envelope of 15 billion Danish Kroner (DKK).
The first tranche permits buybacks worth up to 3.8 billion DKK until early May. Between early February and early March, the company acquired approximately 5.33 million B shares at an average price of 276.06 DKK, representing a total transaction value of about 1.47 billion DKK. In the first week of March alone, daily repurchases ranged from 250,000 to 265,000 shares.
By securing this agreement, Novo Nordisk gains direct access to a broader patient base while curtailing unregulated competition. Combined with the ongoing share repurchases under the first tranche, the company is reinforcing its structural position in the ongoing battle for dominance in the obesity market.
Ad
Novo Nordisk Stock: Buy or Sell?! New Novo Nordisk Analysis from March 10 delivers the answer:
The latest Novo Nordisk figures speak for themselves: Urgent action needed for Novo Nordisk investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 10.
Novo Nordisk: Buy or sell? Read more here...
